- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Scientists Discover Genetic Variants Responsible for Mucinous Ovarian Cancer
Scientists have identified 3 gene variants of HOXD9, which can help explain the development of ovarian cancer.
Scientists at the Keck School of Medicine, University of Southern California, have identified 3 gene variants of HOXD9, which can help explain the development of the fourth most common cause of cancer in the United States, ovarian cancer.
"By finding these genetic markers, we begin to understand more about the biology of the disease itself," said Dr Simon Gayther, the corresponding author on the manuscript that was published in Nature Genetics, in a statement.
The retrospective study was conducted in 1644 women diagnosed with mucinous ovarian cancer and 21000 women without the disease, under the umbrella of the Collaborative Oncological Gene-environment Study, created to determine the risks of breast, ovarian, and prostate cancer.
Read more on ScienceDaily: http://bit.ly/1IiNBKp
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More
